Skip to main content

Table 3 Reason for DI therapy, number of DI cycles, DI response, and patient outcome (n = 9)

From: A study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors

UPN

Reason for DI therapy

No. of DI cycles administered

Study progress

Best response

Outcome

PFS (months)

Follow-up period (months)

1

SPD

14

Completed

CR

DOD

12.4

17.1

2

2nd relapse

3

Stopped

PD

DOD

2.2

24.6

3

PPD

1

Stopped

PD

DOD

0.5

1.5

4

PPD

2

Stopped

PD

DOD

1.4

1.9

5

PPD

1

Stopped

PD

DOD

0.5

1

6

SPD

15

Completed

PR*

AWD

16.9

41.3

7

PPD

2

Stopped

PD

DOD

1.4

6.2

8

PPD

4

Stopped

SD

DOD

3.1

10.1

9

3rd relapse

9

Ongoing

PR*

NED

6.4

6.4

  1. *Two patients achieved PR with DI chemotherapy, followed by CR with subsequent resection of pulmonary metastases.
  2. SD was not confirmed in repeat imaging.
  3. Abbreviations: AWD, alive with disease; CR, complete response; DI, docetaxel and irinotecan; DOD, died of disease; NED, no evidence of disease; PD, progressive disease; PFS, progression-free survival; PPD, primary progressive disease; PR, partial response; SD, stable disease; SPD, secondary progressive disease; UPN, unique patient number.